Rafael Holdings, Inc. (RFL)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 5 | 1 | 0 | 0 | 1 | 1 | 1 | - |
| Operating profit | $m | -26 | -36 | ||||||
| Net profit | $m | -10 | -25 | -125 | -2 | -34 | -31 | -33 | - |
| EPS reported | $ | -1.04 | -0.68 | ||||||
| Operating cashflow per share | $ | -0.64 | -0.62 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.64 | -0.62 | ||||||
| Free cash flow | $m | -19 | -32 | ||||||
| Net debt | $m | -52 | -30 | ||||||
| Book value equity | $m | 94 | 75 | ||||||
| Book value per share | $ | 3.21 | 1.47 | ||||||
| Number of shares | m | 29.42 | 51.23 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.53 | 0.66 | ||||||
| P/S LTM | x | 54.22 | 50.74 | ||||||
| P/FCF LTM | x | -2.63 | -1.55 | ||||||
| EV/EBITDA LTM | x | 0.07 | 0.08 | ||||||
| EV/Sales LTM | x | -2.57 | 73.50 | ||||||
| Earnings Yield LTM | % | -61.38% | -31.93% | ||||||
| FCF Yield | % | -38.07% | -64.32% | ||||||
| Quality | |||||||||
| ROE | % | -32.33% | -38.97% | ||||||
| ROIC | % | -23.37% | -44.50% | ||||||
| Operating margin | % | -28.47% | -37.17% | ||||||
| Gross margin | % | +53.98% | +84.39% | ||||||
| FCF/Sales | % | -2064.1% | -3263.7% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +43.96% | +53.85% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -27.35 | -52.43 | ||||||
| Net Debt/EBITDA | x | 1.61 | 0.96 | ||||||
| EBIT/Net interest | x | -39.68 | -73.59 | ||||||
| Net debt/market cap | % | +1.39% | +0.60% | ||||||
| Net debt/Equity | x | -0.55 | -0.40 | ||||||
| Gross debt/equity | x | 0.01 | 0.01 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free